ClinicalTrials.gg
CompletedNCT01709578Updated Aug 8, 2017Results posted

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

A Phase 3 interventional study of Sarilumab and placebo in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 196 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-08.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
546
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
4th of 22
546 · median 88
Started
2012
the only one that year
Phase 3
9 of 22
1 open now
Registered
8th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 4th largest by enrollment, is the only one that started in 2012, is one of 9 in phase 3, and was the 8th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) were effective for:

  • reduction of signs and symptoms at Week 24 and
  • improvement of physical function at Week 12

in participants with active rheumatoid arthritis (RA) who were inadequate responders or intolerant to tumor necrosis factor alpha (TNF-α) antagonists.

Secondary Objectives:

The secondary objectives were to investigate the effects of SAR153191 (REGN88) when added to DMARD therapy, in participants with active RA who were inadequate responders or intolerant to TNF-α antagonists, for:

  • Reduction of signs and symptoms at Week 12;
  • Improvement in physical function at Week 24;
  • Improvement in disease activity score as measured by other American College of Rheumatology (ACR) derived components at Weeks 12 and 24;
  • Improvement in quality of life as measured by participant reported outcomes (PROs) at intermediate visits and Week 24.

To assess the exposure of sarilumab added to DMARD therapy in this population.

To assess the safety of sarilumab in this population.

Read the detailed description

Total study duration was up to 34 weeks: screening up to 28 days, treatment phase of 24 weeks, and post-treatment follow-up of 6 weeks.

After completion of the treatment phase of this study, participant were eligible to enter a long term safety study (LTS11210) for active treatment with SAR153191 (REGN88).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of RA ≥6 months duration, according to the ACR /European League against Rheumatism (EULAR) 2010 RA Classification Criteria

ACR Class I-III functional status, based on 1991 revised criteria

Anti-TNF therapy failures, defined by the investigator as participants with an inadequate clinical response, after being treated for at least 3 consecutive months, and/or intolerance to at least 1 anti-TNF blocker(s), resulting in or requiring their discontinuation:

  • TNF-blockers included, but were not limited to, etanercept, infliximab, adalimumab, golimumab and/or certolizumab

Moderate-to-severely active RA

Continuous treatment with one or a combination of DMARDs (except for simultaneous combination use of leflunomide and methotrexate) for at least 12 weeks prior to baseline and on a stable dose(s) for at least 6 weeks prior to screening:

  • Methotrexate - 6 to 25 mg/week orally or parenterally
  • Leflunomide - 10 to 20 mg orally daily
  • Sulfasalazine - 1000 to 3000 mg orally daily
  • Hydroxychloroquine - 200 to 400 mg orally daily

Exclusion criteria

Exclusion criteria:

Participants \<18 years of age or legal adult age

Past history of, or current, or inflammatory systemic or localized joint disease(s) other than RA

History of juvenile idiopathic arthritis or arthritis onset prior to age 16

Severe active systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome.

Treatment with anti-TNF agents, as follows:

  • Within 28 days prior to the baseline visit - etanercept
  • Within 42 days prior to the baseline visit - infliximab, adalimumab, golimumab, certolizumab pegol

Treatment with previous RA-directed biologic agents with other than TNF antagonist mechanisms:

Within 28 days prior to the randomization (baseline) visit - anakinra Within 42 days prior to the randomization (baseline) visit - abatacept

Within 6 months prior to the randomization (baseline) visit - any cell depleting agents including but not limited to rituximab without a normal lymphocyte and cluster of differentiation (CD) 19+ lymphocyte count

Treatment with any DMARD other than those allowed per protocol and limited to the maximum specified dosage within 12 weeks prior to baseline

Treatment with prednisone >10 mg or equivalent per day, or change in dosage within 4 weeks prior to baseline visit

Any parenteral or intra-articular injection within 4 weeks prior to baseline

Prior treatment with anti-interleukin (IL) -6 or IL-6 receptor antagonist therapies, including tocilizumab or sarilumab, participation in a prior study of sarilumab, irrespective of treatment arm

Prior treatment with a Janus kinase inhibitor (such as tofacitinib)

New treatment or dose-adjustment to ongoing medication for dyslipidemia within 6 weeks prior to randomization, ie, stable dose for at least 6 weeks prior to randomization

Participation in any clinical research study evaluating another drug or therapy within 5 half-lives or 60 days of first investigational medicinal product (IMP) administration, whichever was longer

History of alcohol or drug abuse within 5 years prior to the screening visit

Participants with a history of other than adequately-treated carcinoma in-situ of the cervix, nonmetastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization (baseline) visit. Nonmalignant lymphoproliferative disorders were also excluded

Participants with active tuberculosis or latent tuberculosis infection

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
546 participants (actual)

Study arms

  • Placebo comparator
    Placebo q2w

    Placebo matched to sarilumab once every 2 weeks (q2w) was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.

    Drug: placebo · Drug: hydroxychloroquine · Drug: methotrexate · Drug: sulfasalazine · Drug: leflunomide

  • Experimental
    Sarilumab 150 mg q2w

    Sarilumab 150 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.

    Drug: Sarilumab · Drug: hydroxychloroquine · Drug: methotrexate · Drug: sulfasalazine · Drug: leflunomide

  • Experimental
    Sarilumab 200 mg q2w

    Sarilumab 200 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.

    Drug: Sarilumab · Drug: hydroxychloroquine · Drug: methotrexate · Drug: sulfasalazine · Drug: leflunomide

Interventions

  • Pharmaceutical form:solution Route of administration: subcutaneous

    Also known as: SAR153191, REGN88

  • Drugplacebo

    Pharmaceutical form:solution Route of administration: subcutaneous

  • Dispensed according to the local practice.

  • Dispensed according to the local practice.

  • Dispensed according to the local practice.

  • Dispensed according to the local practice.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24

    ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: tender joint count (TJC); swollen joint count (SJC); levels of an acute phase reactant (C-reactive Protein levels \[CRP\]); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by (health assessment questionnaire disability index \[HAQ-DI\]). ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR.

    Time frame: Week 24

  2. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12

    Physical function was assessed by HAQ-DI. It consisted of at least 2 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. Least-squares (LS) means and standard errors (SE) at Week 12 were obtained from a mixed-effect model with repeated measures (MMRM) with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline HAQ-DI as a covariate.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 24

    DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR rheumatoid arthritis (RA) core set questionnaire (participant global assessment) in 100 mm visual analog scale (VAS). Marker of inflammation assessed by the high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28 score provides a number indicating the current disease activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission. LS means and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline DAS28-CRP score as a covariate.

    Time frame: Baseline, Week 24

  2. Percentage of Participants Achieving ACR50 Criteria at Week 24

    ACR responses are assessed with a composite rating scale that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR.

    Time frame: Week 24

  3. Percentage of Participants Achieving ACR70 Criteria at Week 24

    ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR.

    Time frame: Week 24

  4. Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 24

    DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH by the participant assessed from the ACR rheumatoid arthritis core set questionnaire (participant global assessment) in 100 mm VAS; marker of inflammation assessed by hs-CRP in mg/L. The DAS28 provides a number indicating the current activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.

    Time frame: Week 24

  5. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

    CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: TJC (28 joints), SJC (28 joints), Participant's Global Assessment of Disease Activity VAS (in cm), and Physician's Global Assessment of Disease VAS (in cm). Total scores ranges from 0 to 76 with a negative change in CDAI score indicating an improvement in disease activity and a positive change in score indicating a worsening of disease activity. LS means and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline CDAI as a covariate.

    Time frame: Baseline, Week 24

  6. Change From Baseline in HAQ-DI at Week 24

    Physical function was assessed by HAQ-DI. It consisted of at least 2 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS means and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline HAQ-DI as a covariate.

    Time frame: Baseline, Week 24

  7. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Component Summary Scores (PCS) at Week 24

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: PCS and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS had 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS had 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being. LS mean and SE at Week 24 by MMRM with treatment,region,number of previous anti TNFs,visit,and treatment-by-visit interaction as fixed effects and baseline SF-36 (PCS) as a covariate.

    Time frame: Baseline, Week 24

  8. Change From Baseline in SF-36 MCS at Week 24

    SF-36 is a generic 36-item questionnaire measuring HRQL covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline SF-36 MCS as a covariate.

    Time frame: Baseline, Week 24

  9. Change From Baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Score at Week 24

    The FACIT-Fatigue is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranging from 0 to 52. A higher score corresponded to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline FACIT-fatigue as a covariate.

    Time frame: Baseline, Week 24

  10. Change From Baseline in Morning Stiffness VAS at Week 24

    RA is associated with stiffness of joints, especially in the morning after prolonged stationery state. The degree of stiffness can be an indicator of disease severity. The severity of morning stiffness was assessed on a VAS scale from 0 mm (no problem) to 100 mm (major problem). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline Morning Stiffness as a covariate.

    Time frame: Baseline, Week 24

  11. Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 24

  12. Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 24

  13. Change From Baseline in WPS-RA at Week 24: RA Interference With Work Productivity

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 24

  14. Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 24

  15. Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by ≥ 50% Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 24

  16. Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 24

  17. Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 24

  18. Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 24

  19. Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Scores at Week 24

    RAID is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well being, quality of sleep, and coping. The RAID is calculated based on 7 numerical rating scales (NRS) questions. Range of the final RAID value is 0-10 where 0= not affected, very good and 10 = most affected weighted and calculated with a total score range of 0 (not affected, very good) to 10 (most affected). A higher RAID value indicate worse status and lower indicate not affected. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline RAID as a covariate.

    Time frame: Baseline, Week 24

  20. Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) VAS Scores at Week 24

    The EQ-5D-3L is a standardized, generic measure of health outcome. It was designed for self-completion by participants. It was specifically included to address concerns regarding the health economic impact of RA. The EQ-5D-3L comprises 5 questions on mobility, self-care, pain, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems) and a vertical VAS that allows the participants to indicate their health state today that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline EQ-5D-3L Scores as a covariate.

    Time frame: Baseline, Week 24

  21. Percentage of Participants Achieving ACR20, ACR50 and ACR70 Criteria at Week 12

    ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR.

    Time frame: Week 12

  22. Change From Baseline in DAS28-CRP at Week 12

    DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH by the participant assessed from the ACR rheumatoid arthritis core set questionnaire (participant global assessment) in 100 mm VAS; marker of inflammation assessed by hs-CRP in mg/L. The DAS28 provides a number indicating the current activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline DAS score as a covariate.

    Time frame: Baseline, Week 12

  23. Percentage of Participants Achieving Clinical Remission Score (DAS28--CRP <2.6) at Week 12

    DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; marker of inflammation assessed by hs-CRP in mg/L. The DAS28 provides a number indicating the current activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.

    Time frame: Week 12

  24. Change From Baseline in SF-36 at Week 12

    SF-36 is a generic 36-item questionnaire measuring HRQL covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline SF-36 as a covariate.

    Time frame: Baseline, Week 12

  25. Change From Baseline in WPS-RA at Week 12: Work Days Missed Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 12

  26. Change From Baseline in WPS-RA at Week 12: Days With Work Productivity Reduced by ≥ 50% Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 12

  27. Change From Baseline in WPS-RA at Week 12: RA Interference With Work Productivity

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 12

  28. Change From Baseline in WPS-RA at Week 12: House Work Days Missed Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 12

  29. Change From Baseline in WPS-RA at Week 12: Days With Household Work Productivity Reduced by ≥ 50% Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 12

  30. Change From Baseline in WPS-RA at Week 12: Days With Family/Social/Leisure Activities Missed Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 12

  31. Change From Baseline in WPS-RA at Week 12: Days With Outside Help Hired Due to RA

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 12

  32. Change From Baseline in WPS-RA at Week 12: RA Interference With Household Work Productivity

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

    Time frame: Baseline, Week 12

  33. Change From Baseline in the FACIT-fatigue at Week 12

    The FACIT-Fatigue is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranging from 0 to 52. A higher score corresponded to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline FACIT-fatigue as a covariate.

    Time frame: Baseline, Week 12

  34. Change From Baseline in EQ-5D-3L VAS Scores at Week 12

    The EQ-5D-3L is a standardized, generic measure of health outcome. EQ-5D was designed for self-completion by participants. The EQ-5D was specifically included to address concerns regarding the health economic impact of RA. The EQ-5D-3L comprises 5 questions on mobility, self-care, pain, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems) and a vertical VAS that allows the participants to indicate their health state today that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline EQ-5D-3L scores as a covariate.

    Time frame: Baseline, Week 12

  35. Change From Baseline in RAID Scores at Week 12

    RAID score is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well being, quality of sleep, and coping. The RAID is calculated based on 7 NRS questions. Range of the final RAID value is 0-10 where 0= not affected, very good and 10 = most affected weighted and calculated with a total score range of 0 (not affected, very good) to 10 (most affected). A higher RAID value indicates worse status and lower indicates not affected. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline RAID scores as a covariate.

    Time frame: Baseline, Week 12

  36. Change From Baseline in Individual ACR Components - TJC and SJC at Week 12 and Week 24

    ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS,HAQ-DI \& CRP. 68 joints were assessed for tenderness (TJC scoring 0-68) and 66 joints for swelling (SJC scoring 0-66). The 66 SJC evaluated the following joints: temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal, interphalangeal of thumb, distal interphalangeal, proximal interphalangeal, knee, ankle mortise, ankle tarsus, metatarsophalangeal, interphalangeal of great toe, and proximal/distal interphalangeal of the toes. The TJC examined hip joints, in addition to the joints assessed for SJC. Increase in number of tender joints/swollen joints indicated severity. LS mean and SE at Week 12 \& 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate.

    Time frame: Baseline, Week 12 and Week 24

  37. Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 12 and Week 24

    ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& CRP. Physician global VAS \& participant global VAS was done by 100 mm non-anchored VAS, from no arthritis (0) activity to maximal arthritis (100) activity. Pain VAS by 100 mm VAS ranging from 0 "no pain" to 100 "worst pain". LS mean and SE at Week 12 \& 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate.

    Time frame: Baseline, Week 12 and Week 24

  38. Change From Baseline in Individual ACR Component - CRP Level at Week 12 and Week 24

    ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& CRP. An elevated CRP level was considered a non-specific "marker" for RA. A reduction level indicates improvement. LS mean and SE at Week 12 \& 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate.

    Time frame: Baseline, Week 12 and Week 24

  39. Change From Baseline in Individual ACR Component - HAQ-DI at Week 12 and Week 24

    ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS,HAQ-DI \& CRP. HAQ-DI consisted of at least 2 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS mean and SE at Week 12 \& 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate.

    Time frame: Baseline, Week 12 and Week 24

07

Results

Posted Aug 8, 2017

Participant flow

The study was conducted at 240 centers in 27 countries. A total of 1224 participants were screened between 29 October 2012 and 7 August 2014, of whom 546 participants were randomized and 678 were screen failures. Screen failures were mainly due to failure to meet inclusion criteria.

Participant flow — Overall Study
MilestonePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Started181181184
Completed101125133
Not completed805651
Withdrew: Rescued and entered in long term safety632526
Withdrew: Adverse event91817
Withdrew: Lack of efficacy542
Withdrew: Poor compliance to protocol121
Withdrew: Other, not related to safety or efficacy275

Outcome measures

PrimaryPercentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24

ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: tender joint count (TJC); swollen joint count (SJC); levels of an acute phase reactant (C-reactive Protein levels \[CRP\]); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by (health assessment questionnaire disability index \[HAQ-DI\]). ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24
percentage of participantsPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 2433.755.860.9
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mantel Haenszel · p = <0.0001 (Threshold for significance at 0.025 level) · Odds ratio (or): 2.711 · 95% CI 1.730 to 4.247Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mantel Haenszel · p = <0.0001 (Threshold for significance at 0.025 level) · Odds ratio (or): 3.284 · 95% CI 2.108 to 5.115Sarilumab 200 mg q2w vs Placebo q2w
PrimaryChange From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12

Physical function was assessed by HAQ-DI. It consisted of at least 2 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. Least-squares (LS) means and standard errors (SE) at Week 12 were obtained from a mixed-effect model with repeated measures (MMRM) with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline HAQ-DI as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12-0.26 ± 0.043-0.46 ± 0.044-0.47 ± 0.043
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mixed Models Analysis · p = 0.0007 (Threshold for significance at 0.025 level) · Ls mean difference: -0.202 · 95% CI -0.318 to -0.086Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mixed Models Analysis · p = 0.0004 (Threshold for significance at 0.025 level) · Ls mean difference: -0.210 · 95% CI -0.325 to -0.095Sarilumab 200 mg q2w vs Placebo q2w
SecondaryChange From Baseline in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 24

DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR rheumatoid arthritis (RA) core set questionnaire (participant global assessment) in 100 mm visual analog scale (VAS). Marker of inflammation assessed by the high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28 score provides a number indicating the current disease activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission. LS means and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline DAS28-CRP score as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 24
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 24-1.38 ± 0.119-2.35 ± 0.111-2.82 ± 0.108
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level) · Ls mean difference: -0.971 · 95% CI -1.283 to -0.658Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level) · Ls mean difference: -1.444 · 95% CI -1.752 to -1.135Sarilumab 200 mg q2w vs Placebo q2w
SecondaryPercentage of Participants Achieving ACR50 Criteria at Week 24

ACR responses are assessed with a composite rating scale that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ACR50 Criteria at Week 24
Percentage of participantsPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Percentage of Participants Achieving ACR50 Criteria at Week 2418.237.040.8
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mantel Haenszel · p = <0.0001 (Threshold for significance at 0.025 level) · Odds ratio (or): 2.958 · 95% CI 1.764 to 4.959Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mantel Haenszel · p = <0.0001 (Threshold for significance was 0.025 level) · Odds ratio (or): 3.374 · 95% CI 2.045 to 5.566Sarilumab 200 mg q2w vs Placebo q2w
SecondaryPercentage of Participants Achieving ACR70 Criteria at Week 24

ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ACR70 Criteria at Week 24
Percentage of participantsPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Percentage of Participants Achieving ACR70 Criteria at Week 247.219.916.3
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mantel Haenszel · p = 0.0002 (Threshold for significance at 0.025 level) · Odds ratio (or): 3.607 · 95% CI 1.774 to 7.332Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mantel Haenszel · p = 0.0056 (Threshold for significance at 0.025 level) · Odds ratio (or): 2.653 · 95% CI 1.308 to 5.383Sarilumab 200 mg q2w vs Placebo q2w
SecondaryPercentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 24

DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH by the participant assessed from the ACR rheumatoid arthritis core set questionnaire (participant global assessment) in 100 mm VAS; marker of inflammation assessed by hs-CRP in mg/L. The DAS28 provides a number indicating the current activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 24
Percentage of participantsPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 247.224.928.8
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mantel Haenszel · p = <0.0001 (Threshold for significance at 0.025 level) · Odds ratio (or): 4.622 · 95% CI 2.339 to 9.132Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mantel Haenszel · p = <0.0001 (Threshold for significance at 0.025 level) · Odds ratio (or): 5.801 · 95% CI 2.948 to 11.413Sarilumab 200 mg q2w vs Placebo q2w
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: TJC (28 joints), SJC (28 joints), Participant's Global Assessment of Disease Activity VAS (in cm), and Physician's Global Assessment of Disease VAS (in cm). Total scores ranges from 0 to 76 with a negative change in CDAI score indicating an improvement in disease activity and a positive change in score indicating a worsening of disease activity. LS means and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline CDAI as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24-16.35 ± 1.195-23.65 ± 1.136-26.08 ± 1.109
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level) · Ls mean difference: -7.306 · 95% CI -10.444 to -4.167Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level) · Ls mean difference: -9.727 · 95% CI -12.833 to -6.622Sarilumab 200 mg q2w vs Placebo q2w
SecondaryChange From Baseline in HAQ-DI at Week 24

Physical function was assessed by HAQ-DI. It consisted of at least 2 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS means and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline HAQ-DI as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in HAQ-DI at Week 24
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in HAQ-DI at Week 24-0.34 ± 0.051-0.52 ± 0.049-0.58 ± 0.048
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mixed Models Analysis · p = 0.0078 (Threshold for significance was 0.025 level) · Ls mean difference: -0.183 · 95% CI -0.318 to -0.048Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mixed Models Analysis · p = 0.0004 (Threshold for significance was 0.025 level) · Ls mean difference: -0.242 · 95% CI -0.376 to -0.109Sarilumab 200 mg q2w vs Placebo q2w
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Component Summary Scores (PCS) at Week 24

SF-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: PCS and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS had 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS had 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being. LS mean and SE at Week 24 by MMRM with treatment,region,number of previous anti TNFs,visit,and treatment-by-visit interaction as fixed effects and baseline SF-36 (PCS) as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Component Summary Scores (PCS) at Week 24
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Component Summary Scores (PCS) at Week 244.40 ± 0.6927.65 ± 0.6538.48 ± 0.630
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mixed Models Analysis · p = 0.0004 (Threshold for significance at 0.025 level) · Ls mean difference: 3.250 · 95% CI 1.450 to 5.049Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level) · Ls mean difference: 4.075 · 95% CI 2.305 to 5.846Sarilumab 200 mg q2w vs Placebo q2w
SecondaryChange From Baseline in SF-36 MCS at Week 24

SF-36 is a generic 36-item questionnaire measuring HRQL covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline SF-36 MCS as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in SF-36 MCS at Week 24
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in SF-36 MCS at Week 244.74 ± 0.9026.26 ± 0.8486.76 ± 0.817
Statistical analysis
  • Placebo q2w vs Sarilumab 150 mg q2w · Mixed Models Analysis · p = 0.2026 (Threshold for significance at 0.025 level) · Ls mean difference: 1.515 · 95% CI -0.818 to 3.848Sarilumab 150 mg q2w vs Placebo q2w
  • Placebo q2w vs Sarilumab 200 mg q2w · Mixed Models Analysis · p = 0.0854 (Threshold for significance at 0.025 level) · Ls mean difference: 2.013 · 95% CI -0.282 to 4.309Sarilumab 200 mg q2w vs Placebo q2w
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Score at Week 24

The FACIT-Fatigue is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranging from 0 to 52. A higher score corresponded to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline FACIT-fatigue as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Score at Week 24
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Score at Week 246.82 ± 0.8639.86 ± 0.80210.06 ± 0.778
SecondaryChange From Baseline in Morning Stiffness VAS at Week 24

RA is associated with stiffness of joints, especially in the morning after prolonged stationery state. The degree of stiffness can be an indicator of disease severity. The severity of morning stiffness was assessed on a VAS scale from 0 mm (no problem) to 100 mm (major problem). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline Morning Stiffness as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mm
Change From Baseline in Morning Stiffness VAS at Week 24
mmPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in Morning Stiffness VAS at Week 24-21.66 ± 2.390-32.30 ± 2.213-33.79 ± 2.148
SecondaryChange From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Days
Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to RA-2.01 ± 0.458-2.87 ± 0.438-3.19 ± 0.447
SecondaryChange From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to RA-3.64 ± 0.589-4.26 ± 0.521-4.34 ± 0.535
SecondaryChange From Baseline in WPS-RA at Week 24: RA Interference With Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in WPS-RA at Week 24: RA Interference With Work Productivity
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 24: RA Interference With Work Productivity-1.632 ± 0.4186-2.422 ± 0.3719-2.727 ± 0.3700
SecondaryChange From Baseline in WPS-RA at Week 24: House Work Days Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to RA-3.50 ± 0.590-6.13 ± 0.551-6.18 ± 0.537
SecondaryChange From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by ≥ 50% Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by ≥ 50% Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by ≥ 50% Due to RA-3.36 ± 0.632-4.60 ± 0.591-4.88 ± 0.574
SecondaryChange From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to RA-1.97 ± 0.479-3.51 ± 0.446-4.12 ± 0.435
SecondaryChange From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to RA-1.60 ± 0.567-3.87 ± 0.536-3.86 ± 0.523
SecondaryChange From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity-1.970 ± 0.2438-3.096 ± 0.2238-3.269 ± 0.2186
SecondaryChange From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Scores at Week 24

RAID is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well being, quality of sleep, and coping. The RAID is calculated based on 7 numerical rating scales (NRS) questions. Range of the final RAID value is 0-10 where 0= not affected, very good and 10 = most affected weighted and calculated with a total score range of 0 (not affected, very good) to 10 (most affected). A higher RAID value indicate worse status and lower indicate not affected. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline RAID as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Scores at Week 24
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Scores at Week 24-1.80 ± 0.203-2.55 ± 0.189-2.80 ± 0.183
SecondaryChange From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) VAS Scores at Week 24

The EQ-5D-3L is a standardized, generic measure of health outcome. It was designed for self-completion by participants. It was specifically included to address concerns regarding the health economic impact of RA. The EQ-5D-3L comprises 5 questions on mobility, self-care, pain, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems) and a vertical VAS that allows the participants to indicate their health state today that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline EQ-5D-3L Scores as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) VAS Scores at Week 24
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) VAS Scores at Week 2414.85 ± 2.09820.06 ± 1.89118.40 ± 1.842
SecondaryPercentage of Participants Achieving ACR20, ACR50 and ACR70 Criteria at Week 12

ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ACR20, ACR50 and ACR70 Criteria at Week 12
Percentage of participantsPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
ACR2037.654.162.5
ACR5013.330.433.2
ACR702.213.814.7
SecondaryChange From Baseline in DAS28-CRP at Week 12

DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH by the participant assessed from the ACR rheumatoid arthritis core set questionnaire (participant global assessment) in 100 mm VAS; marker of inflammation assessed by hs-CRP in mg/L. The DAS28 provides a number indicating the current activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline DAS score as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in DAS28-CRP at Week 12
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in DAS28-CRP at Week 12-0.97 ± 0.104-2.13 ± 0.105-2.45 ± 0.103
SecondaryPercentage of Participants Achieving Clinical Remission Score (DAS28--CRP <2.6) at Week 12

DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; marker of inflammation assessed by hs-CRP in mg/L. The DAS28 provides a number indicating the current activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission Score (DAS28--CRP <2.6) at Week 12
Percentage of participantsPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Percentage of Participants Achieving Clinical Remission Score (DAS28--CRP <2.6) at Week 123.917.117.9
SecondaryChange From Baseline in SF-36 at Week 12

SF-36 is a generic 36-item questionnaire measuring HRQL covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline SF-36 as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in SF-36 at Week 12
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Physical Component Summary Score at Week 123.74 ± 0.5826.93 ± 0.5966.84 ± 0.584
Mental Component Summary Score at Week 123.50 ± 0.7385.14 ± 0.7586.47 ± 0.741
SecondaryChange From Baseline in WPS-RA at Week 12: Work Days Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 12: Work Days Missed Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 12: Work Days Missed Due to RA-1.20 ± 0.581-1.97 ± 0.571-2.98 ± 0.585
SecondaryChange From Baseline in WPS-RA at Week 12: Days With Work Productivity Reduced by ≥ 50% Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 12: Days With Work Productivity Reduced by ≥ 50% Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 12: Days With Work Productivity Reduced by ≥ 50% Due to RA-1.69 ± 0.784-4.24 ± 0.773-3.20 ± 0.785
SecondaryChange From Baseline in WPS-RA at Week 12: RA Interference With Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in WPS-RA at Week 12: RA Interference With Work Productivity
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 12: RA Interference With Work Productivity-1.043 ± 0.3803-1.924 ± 0.3742-1.873 ± 0.3764
SecondaryChange From Baseline in WPS-RA at Week 12: House Work Days Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 12: House Work Days Missed Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 12: House Work Days Missed Due to RA-2.10 ± 0.551-5.52 ± 0.563-5.54 ± 0.553
SecondaryChange From Baseline in WPS-RA at Week 12: Days With Household Work Productivity Reduced by ≥ 50% Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 12: Days With Household Work Productivity Reduced by ≥ 50% Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 12: Days With Household Work Productivity Reduced by ≥ 50% Due to RA-2.60 ± 0.576-3.97 ± 0.587-3.98 ± 0.575
SecondaryChange From Baseline in WPS-RA at Week 12: Days With Family/Social/Leisure Activities Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 12: Days With Family/Social/Leisure Activities Missed Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 12: Days With Family/Social/Leisure Activities Missed Due to RA-2.23 ± 0.433-2.53 ± 0.442-3.26 ± 0.434
SecondaryChange From Baseline in WPS-RA at Week 12: Days With Outside Help Hired Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Days
Change From Baseline in WPS-RA at Week 12: Days With Outside Help Hired Due to RA
DaysPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 12: Days With Outside Help Hired Due to RA-0.77 ± 0.558-3.07 ± 0.570-2.94 ± 0.560
SecondaryChange From Baseline in WPS-RA at Week 12: RA Interference With Household Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in WPS-RA at Week 12: RA Interference With Household Work Productivity
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in WPS-RA at Week 12: RA Interference With Household Work Productivity-1.210 ± 0.2428-2.772 ± 0.2474-2.404 ± 0.2443
SecondaryChange From Baseline in the FACIT-fatigue at Week 12

The FACIT-Fatigue is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranging from 0 to 52. A higher score corresponded to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline FACIT-fatigue as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the FACIT-fatigue at Week 12
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in the FACIT-fatigue at Week 125.56 ± 0.7218.02 ± 0.7299.45 ± 0.714
SecondaryChange From Baseline in EQ-5D-3L VAS Scores at Week 12

The EQ-5D-3L is a standardized, generic measure of health outcome. EQ-5D was designed for self-completion by participants. The EQ-5D was specifically included to address concerns regarding the health economic impact of RA. The EQ-5D-3L comprises 5 questions on mobility, self-care, pain, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems) and a vertical VAS that allows the participants to indicate their health state today that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline EQ-5D-3L scores as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in EQ-5D-3L VAS Scores at Week 12
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in EQ-5D-3L VAS Scores at Week 128.39 ± 1.69917.16 ± 1.72015.23 ± 1.680
SecondaryChange From Baseline in RAID Scores at Week 12

RAID score is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well being, quality of sleep, and coping. The RAID is calculated based on 7 NRS questions. Range of the final RAID value is 0-10 where 0= not affected, very good and 10 = most affected weighted and calculated with a total score range of 0 (not affected, very good) to 10 (most affected). A higher RAID value indicates worse status and lower indicates not affected. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline RAID scores as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in RAID Scores at Week 12
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in RAID Scores at Week 12-1.34 ± 0.163-2.27 ± 0.165-2.47 ± 0.161
SecondaryChange From Baseline in Individual ACR Components - TJC and SJC at Week 12 and Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS,HAQ-DI \& CRP. 68 joints were assessed for tenderness (TJC scoring 0-68) and 66 joints for swelling (SJC scoring 0-66). The 66 SJC evaluated the following joints: temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal, interphalangeal of thumb, distal interphalangeal, proximal interphalangeal, knee, ankle mortise, ankle tarsus, metatarsophalangeal, interphalangeal of great toe, and proximal/distal interphalangeal of the toes. The TJC examined hip joints, in addition to the joints assessed for SJC. Increase in number of tender joints/swollen joints indicated severity. LS mean and SE at Week 12 \& 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · joints
Change From Baseline in Individual ACR Components - TJC and SJC at Week 12 and Week 24
jointsPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
TJC at week 12-8.55 ± 0.959-13.74 ± 0.975-14.87 ± 0.954
SJC at week 12-6.75 ± 0.687-10.54 ± 0.698-10.59 ± 0.684
TJC at week 24-10.55 ± 1.060-14.44 ± 1.017-16.95 ± 0.992
SJC at week 24-8.19 ± 0.721-11.56 ± 0.691-11.94 ± 0.674
SecondaryChange From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 12 and Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& CRP. Physician global VAS \& participant global VAS was done by 100 mm non-anchored VAS, from no arthritis (0) activity to maximal arthritis (100) activity. Pain VAS by 100 mm VAS ranging from 0 "no pain" to 100 "worst pain". LS mean and SE at Week 12 \& 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · mm
Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 12 and Week 24
mmPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
Physician global VAS at week 12-22.74 ± 1.744-33.64 ± 1.775-35.44 ± 1.740
Participant global VAS at week 12-13.75 ± 1.807-25.28 ± 1.836-27.38 ± 1.803
Pain VAS at week 12-15.13 ± 1.908-26.93 ± 1.933-30.56 ± 1.901
Physician global VAS at week 24-28.55 ± 1.806-40.65 ± 1.695-43.22 ± 1.646
Participant global VAS at week 24-19.76 ± 2.171-29.59 ± 2.046-31.28 ± 1.997
Pain VAS at week 24-21.27 ± 2.250-31.90 ± 2.086-33.65 ± 2.037
SecondaryChange From Baseline in Individual ACR Component - CRP Level at Week 12 and Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& CRP. An elevated CRP level was considered a non-specific "marker" for RA. A reduction level indicates improvement. LS mean and SE at Week 12 \& 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · mg/L
Change From Baseline in Individual ACR Component - CRP Level at Week 12 and Week 24
mg/LPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
CRP at week 12-3.63 ± 1.436-15.08 ± 1.452-22.98 ± 1.432
CRP at week 24-3.60 ± 1.556-15.24 ± 1.457-23.27 ± 1.421
SecondaryChange From Baseline in Individual ACR Component - HAQ-DI at Week 12 and Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS,HAQ-DI \& CRP. HAQ-DI consisted of at least 2 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS mean and SE at Week 12 \& 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Individual ACR Component - HAQ-DI at Week 12 and Week 24
units on a scalePlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
HAQ-DI at week 12-0.26 ± 0.043-0.46 ± 0.044-0.47 ± 0.043
HAQ-DI at week 24-0.34 ± 0.051-0.52 ± 0.049-0.58 ± 0.048

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 30) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo q2w—6/181 (3.3%)26/181 (14.4%)
Sarilumab 150 mg q2w—6/181 (3.3%)60/181 (33.1%)
Sarilumab 200 mg q2w—10/184 (5.4%)57/184 (31%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
BacteraemiaInfections and infestations1/1810/1810/184
BronchitisInfections and infestations1/1810/1810/184
CellulitisInfections and infestations1/1811/1811/184
OsteomyelitisInfections and infestations0/1811/1810/184
Ureteric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1810/1810/184
AnaemiaBlood and lymphatic system disorders1/1810/1810/184
NeutropeniaBlood and lymphatic system disorders0/1811/1811/184
SyncopeNervous system disorders0/1811/1810/184
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1811/1810/184
Gastric ulcer haemorrhageGastrointestinal disorders0/1811/1810/184
Most frequent other events
Most frequent other events
EventPlacebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2w
NeutropeniaBlood and lymphatic system disorders2/18123/18122/184
Urinary tract infectionInfections and infestations12/1816/18113/184
NasopharyngitisInfections and infestations9/18111/1817/184
HypertriglyceridaemiaMetabolism and nutrition disorders3/18111/1815/184
Injection site erythemaGeneral disorders0/18111/1817/184
Alanine aminotransferase increasedInvestigations2/1815/18110/184

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2wTotal
Mean51.9 ± 12.454.0 ± 11.752.9 ± 12.952.9 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo q2wSarilumab 150 mg q2wSarilumab 200 mg q2wTotal
Female154142151447
Male27393399
08

Study locations

196 sites
  • Investigational Site Number 840070
    Anniston, Alabama 36207, United States
  • Investigational Site Number 840138
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 840142
    Phoenix, Arizona 85037, United States
  • Investigational Site Number 840134
    Fullerton, California 92835, United States
  • Investigational Site Number 840141
    Glendale, California 85304, United States
  • Investigational Site Number 840111
    La Jolla, California 92037, United States
  • Investigational Site Number 840135
    San Diego, California 92120, United States
  • Investigational Site Number 840021
    Santa Maria, California 94354, United States
  • Investigational Site Number 840100
    Stanford, California 94305, United States
  • Investigational Site Number 840049
    Upland, California 91786, United States
  • Investigational Site Number 840131
    Whittier, California 90606, United States
  • Investigational Site Number 840201
    Denver, Colorado 80230, United States
  • Investigational Site Number 840130
    Lewes, Delaware 19958, United States
  • Investigational Site Number 840125
    DeBary, Florida 32713, United States
  • Investigational Site Number 840048
    Miami, Florida 33155, United States
  • Investigational Site Number 840024
    Naples, Florida 34102, United States
  • Investigational Site Number 840006
    Orlando, Florida 32806, United States
  • Investigational Site Number 840128
    Ormond Beach, Florida 32174, United States
  • Investigational Site Number 840063
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840060
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840140
    Tampa, Florida 33614, United States
  • Investigational Site Number 840126
    Vero Beach, Florida 32960, United States
  • Investigational Site Number 840018
    Idaho Falls, Idaho 83404, United States
  • Investigational Site Number 840110
    Meridian, Idaho 83642, United States
  • Investigational Site Number 840052
    Kansas City, Kansas 66160-7321, United States
  • Investigational Site Number 840015
    Lexington, Kentucky 40504, United States
  • Investigational Site Number 840120
    Baton Rouge, Louisiana 70809, United States
  • Investigational Site Number 840109
    Lake Charles, Louisiana 70601, United States
  • Investigational Site Number 840055
    Frederick, Maryland 21702, United States
  • Investigational Site Number 840150
    Lansing, Michigan 48910, United States
  • Investigational Site Number 840137
    Saint Clair Shores, Michigan 48081, United States
  • Investigational Site Number 840037
    Tupelo, Mississippi 38801, United States
  • Investigational Site Number 840112
    Lincoln, Nebraska 68516, United States
  • Investigational Site Number 840106
    Orchard Park, New York 14127, United States
  • Investigational Site Number 840121
    Rochester, New York 14609, United States
  • Investigational Site Number 840115
    Roslyn, New York 11576, United States
  • Investigational Site Number 840118
    Smithtown, New York 11787, United States
  • Investigational Site Number 840139
    Syracuse, New York 13210, United States
  • Investigational Site Number 840123
    Charlotte, North Carolina 28210, United States
  • Investigational Site Number 840116
    Wilmington, North Carolina 28401, United States
  • Investigational Site Number 840127
    Oklahoma City, Oklahoma 73103, United States
  • Investigational Site Number 840011
    Tulsa, Oklahoma 74104, United States
  • Investigational Site Number 840009
    Duncansville, Pennsylvania 16635, United States
  • Investigational Site Number 840117
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site Number 840062
    Reading, Pennsylvania 19611, United States
  • Investigational Site Number 840058
    Columbia, South Carolina 29204, United States
  • Investigational Site Number 840025
    Jackson, Tennessee 38305, United States
  • Investigational Site Number 840059
    Memphis, Tennessee 38119, United States
  • Investigational Site Number 840132
    Austin, Texas 78731, United States
  • Investigational Site Number 840022
    Dallas, Texas 75235, United States
  • Investigational Site Number 840114
    El Paso, Texas 79902, United States
  • Investigational Site Number 840133
    Houston, Texas 77008, United States
  • Investigational Site Number 840129
    Houston, Texas 77074, United States
  • Investigational Site Number 840074
    Mesquite, Texas 75150, United States
  • Investigational Site Number 840036
    Spokane, Washington 99204, United States
  • Investigational Site Number 840124
    Clarksburg, West Virginia 26301, United States
  • Investigational Site Number 032015
    Buenos Aires, 32015, Argentina
  • Investigational Site Number 032008
    Buenos Aires, C1428DZF, Argentina
  • Investigational Site Number 032019
    Caba, 1180, Argentina
  • Investigational Site Number 032006
    Caba, C1015ABO, Argentina
  • Investigational Site Number 032016
    Capital Federal, 1425, Argentina
  • Investigational Site Number 032020
    Cordoba, X5119XAA, Argentina
  • Investigational Site Number 032017
    La Plata, Argentina
  • Investigational Site Number 032010
    Ramos Mejia, B1704ETD, Argentina
  • Investigational Site Number 032013
    Rosario, S2000PBJ, Argentina
  • Investigational Site Number 032004
    San Miguel De Tucuman, T4000AXL, Argentina
  • Investigational Site Number 032009
    Zarate, B2800DGH, Argentina
  • Investigational Site Number 036014
    Victoria Park, 6100, Australia
  • Investigational Site Number 040004
    Stockerau, 2000, Austria
  • Investigational Site Number 040003
    Wien, 1090, Austria
  • Investigational Site Number 076001
    Curitiba, 80060-240, Brazil
  • Investigational Site Number 076016
    Curitiba, Brazil
  • Investigational Site Number 076006
    Goiania, 74110-120, Brazil
  • Investigational Site Number 076010
    Juiz De Fora, 36010-570, Brazil
  • Investigational Site Number 076005
    Rio De Janeiro, 20551-030, Brazil
  • Investigational Site Number 076015
    Rio De Janeiro, 22271-100, Brazil
  • Investigational Site Number 124005
    Toronto, M5T 2S8, Canada
  • Investigational Site Number 124009
    Trois-Rivières, G8Z 1Y2, Canada
  • Investigational Site Number 124104
    Victoria, V8V 3P9, Canada
  • Investigational Site Number 152015
    Temuco, Chile
  • Investigational Site Number 170001
    Bogota, Colombia
  • Investigational Site Number 170012
    Bogota, Colombia
  • Investigational Site Number 170006
    Bogotá, Colombia
  • Investigational Site Number 170007
    Bucaramanga, Colombia
  • Investigational Site Number 170009
    Bucaramanga, Colombia
  • Investigational Site Number 170014
    Chia, Colombia
  • Investigational Site Number 170019
    Medellin, Colombia
  • Investigational Site Number 203008
    Hostivice, 233 01, Czechia
  • Investigational Site Number 203004
    Ostrava, 702 00, Czechia
  • Investigational Site Number 203007
    Praha 2, 12850, Czechia
  • Investigational Site Number 203002
    Uherske Hradiste, 686 01, Czechia
  • Investigational Site Number 203006
    Zlin, 76001, Czechia
  • Investigational Site Number 218003
    Cuenca, Ecuador
  • Investigational Site Number 218001
    Guayaquil, 0593, Ecuador
  • Investigational Site Number 218002
    Quito, 0593, Ecuador
  • Investigational Site Number 276011
    Bad Nauheim, 61231, Germany
  • Investigational Site Number 276010
    Berlin, 10117, Germany
  • Investigational Site Number 276001
    Berlin, 12305, Germany
  • Investigational Site Number 276014
    Berlin, 14059, Germany
  • Investigational Site Number 276018
    Deggingen, 73326, Germany

Showing the first 100 of 196 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2017 Feb;69(2):277-290. doi: 10.1002/art.39944. PubMed 27860410 ↗
  • Rubbert-Roth A, Furst DE, Fiore S, Praestgaard A, Bykerk V, Bingham CO, Charles-Schoeman C, Burmester G. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. Arthritis Res Ther. 2022 Aug 25;24(1):207. doi: 10.1186/s13075-022-02891-x. PubMed 36008838 ↗
  • Rehberg M, Giegerich C, Praestgaard A, van Hoogstraten H, Iglesias-Rodriguez M, Curtis JR, Gottenberg JE, Schwarting A, Castaneda S, Rubbert-Roth A, Choy EHS; MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatol Ther. 2021 Dec;8(4):1661-1675. doi: 10.1007/s40744-021-00361-5. Epub 2021 Sep 14. Erratum In: Rheumatol Ther. 2021 Dec;8(4):1921-1922. doi: 10.1007/s40744-021-00389-7. PubMed 34519964 ↗
  • Fleischmann R, Genovese MC, Maslova K, Leher H, Praestgaard A, Burmester GR. Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. Rheumatology (Oxford). 2021 Nov 3;60(11):4991-5001. doi: 10.1093/rheumatology/keab355. PubMed 33871596 ↗
  • Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, John GS, Gonzalez-Gay MA, Mandrup-Poulsen T, Fleischmann R. Interleukin-6 receptor blockade or TNFalpha inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 2020 Sep 9;22(1):206. doi: 10.1186/s13075-020-02229-5. PubMed 32907617 ↗
  • Genovese MC, Fleischmann R, Kivitz A, Lee EB, van Hoogstraten H, Kimura T, St John G, Mangan EK, Burmester GR. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Res Ther. 2020 Jun 10;22(1):139. doi: 10.1186/s13075-020-02194-z. PubMed 32522251 ↗
  • Gossec L, Strand V, Proudfoot C, Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. J Rheumatol. 2019 Oct;46(10):1259-1267. doi: 10.3899/jrheum.180904. Epub 2019 Mar 15. PubMed 30877216 ↗
  • Gabay C, Msihid J, Zilberstein M, Paccard C, Lin Y, Graham NMH, Boyapati A. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study. RMD Open. 2018 Mar 14;4(1):e000607. doi: 10.1136/rmdopen-2017-000607. eCollection 2018. PubMed 29556418 ↗
  • Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. RMD Open. 2017 Mar 7;3(1):e000416. doi: 10.1136/rmdopen-2016-000416. eCollection 2017. PubMed 28326189 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 2 years 5 months after primary completion. A results delay was requested in Nov 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2012
First posted
Oct 18, 2012
Start
Oct 2012
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results delay requested
Nov 16, 2015
Results first posted
Aug 8, 2017
Last update
Aug 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01709578
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Oct 2012
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Aug 8, 2017
Last update
Aug 8, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion